A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: The St Jude long-term follow-up

K. A. Kasow, C. F. Stewart, R. C. Barfield, N. L. Wright, Chin-Shang Li, D. K. Srivastava, W. Leung, E. M. Horwitz, L. C. Bowman, R. Handgretinger, G. A. Hale

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Fifty-eight consecutive children with high-risk malignancies were treated with CY, and targeted topotecan followed by autologous hematopoietic cell transplantation (AHCT) in a phase I/II Institutional Review Board-approved study. Twelve participants enrolled in phase I; 5 received dose level 1 of topotecan 3 mg/m2 per day, with subsequent doses targeted to total systemic exposure of 100±20 ng h/mL and CY 750 mg/m2 per day. Seven participants received dose level 2. CY dose escalation to 1 g/m 2 per day was considered excessively toxic; one died from irreversible veno-occlusive disease and two experienced reversible hepatotoxicity. These adverse events halted further dose escalation. A total of 46 participants were enrolled in phase II; results are on the 51 participants who received therapy at dose level 1, the maximum tolerated dose. Diagnoses included neuroblastoma (26), sarcoma (9), lymphoma (8), brain tumors (5), Wilms (2) and retinoblastoma (1). Twenty participants (39.3%) were in CR1 at enrollment; median age was 5.1 years. Most common non-hematological grade IIIIV toxicity was gastrointestinal (n37). Neutrophil and platelet engraftment occurred at a median of 15 and 24 days, respectively. Twenty-six (51%) participants remain alive at a median of 6.4 years after AHCT. CY 3.75 g/m 2, and targeted topotecan followed by AHCT are feasible and produce acceptable toxicity in children with high-risk malignancies.

Original languageEnglish (US)
Pages (from-to)1448-1454
Number of pages7
JournalBone Marrow Transplantation
Volume47
Issue number11
DOIs
StatePublished - Nov 2012
Externally publishedYes

Fingerprint

Topotecan
Cell Transplantation
Neoplasms
Maximum Tolerated Dose
Retinoblastoma
Poisons
Research Ethics Committees
Neuroblastoma
Brain Neoplasms
Sarcoma
Lymphoma
Neutrophils
Blood Platelets
Therapeutics

Keywords

  • autologous BMT
  • CY
  • lymphoma
  • neuroblastoma
  • sarcoma
  • topotecan

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation : The St Jude long-term follow-up. / Kasow, K. A.; Stewart, C. F.; Barfield, R. C.; Wright, N. L.; Li, Chin-Shang; Srivastava, D. K.; Leung, W.; Horwitz, E. M.; Bowman, L. C.; Handgretinger, R.; Hale, G. A.

In: Bone Marrow Transplantation, Vol. 47, No. 11, 11.2012, p. 1448-1454.

Research output: Contribution to journalArticle

Kasow, KA, Stewart, CF, Barfield, RC, Wright, NL, Li, C-S, Srivastava, DK, Leung, W, Horwitz, EM, Bowman, LC, Handgretinger, R & Hale, GA 2012, 'A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: The St Jude long-term follow-up', Bone Marrow Transplantation, vol. 47, no. 11, pp. 1448-1454. https://doi.org/10.1038/bmt.2012.51
Kasow, K. A. ; Stewart, C. F. ; Barfield, R. C. ; Wright, N. L. ; Li, Chin-Shang ; Srivastava, D. K. ; Leung, W. ; Horwitz, E. M. ; Bowman, L. C. ; Handgretinger, R. ; Hale, G. A. / A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation : The St Jude long-term follow-up. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 11. pp. 1448-1454.
@article{d9a506b9ac5a4e5089bd9ab50f6dbaba,
title = "A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: The St Jude long-term follow-up",
abstract = "Fifty-eight consecutive children with high-risk malignancies were treated with CY, and targeted topotecan followed by autologous hematopoietic cell transplantation (AHCT) in a phase I/II Institutional Review Board-approved study. Twelve participants enrolled in phase I; 5 received dose level 1 of topotecan 3 mg/m2 per day, with subsequent doses targeted to total systemic exposure of 100±20 ng h/mL and CY 750 mg/m2 per day. Seven participants received dose level 2. CY dose escalation to 1 g/m 2 per day was considered excessively toxic; one died from irreversible veno-occlusive disease and two experienced reversible hepatotoxicity. These adverse events halted further dose escalation. A total of 46 participants were enrolled in phase II; results are on the 51 participants who received therapy at dose level 1, the maximum tolerated dose. Diagnoses included neuroblastoma (26), sarcoma (9), lymphoma (8), brain tumors (5), Wilms (2) and retinoblastoma (1). Twenty participants (39.3{\%}) were in CR1 at enrollment; median age was 5.1 years. Most common non-hematological grade IIIIV toxicity was gastrointestinal (n37). Neutrophil and platelet engraftment occurred at a median of 15 and 24 days, respectively. Twenty-six (51{\%}) participants remain alive at a median of 6.4 years after AHCT. CY 3.75 g/m 2, and targeted topotecan followed by AHCT are feasible and produce acceptable toxicity in children with high-risk malignancies.",
keywords = "autologous BMT, CY, lymphoma, neuroblastoma, sarcoma, topotecan",
author = "Kasow, {K. A.} and Stewart, {C. F.} and Barfield, {R. C.} and Wright, {N. L.} and Chin-Shang Li and Srivastava, {D. K.} and W. Leung and Horwitz, {E. M.} and Bowman, {L. C.} and R. Handgretinger and Hale, {G. A.}",
year = "2012",
month = "11",
doi = "10.1038/bmt.2012.51",
language = "English (US)",
volume = "47",
pages = "1448--1454",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation

T2 - The St Jude long-term follow-up

AU - Kasow, K. A.

AU - Stewart, C. F.

AU - Barfield, R. C.

AU - Wright, N. L.

AU - Li, Chin-Shang

AU - Srivastava, D. K.

AU - Leung, W.

AU - Horwitz, E. M.

AU - Bowman, L. C.

AU - Handgretinger, R.

AU - Hale, G. A.

PY - 2012/11

Y1 - 2012/11

N2 - Fifty-eight consecutive children with high-risk malignancies were treated with CY, and targeted topotecan followed by autologous hematopoietic cell transplantation (AHCT) in a phase I/II Institutional Review Board-approved study. Twelve participants enrolled in phase I; 5 received dose level 1 of topotecan 3 mg/m2 per day, with subsequent doses targeted to total systemic exposure of 100±20 ng h/mL and CY 750 mg/m2 per day. Seven participants received dose level 2. CY dose escalation to 1 g/m 2 per day was considered excessively toxic; one died from irreversible veno-occlusive disease and two experienced reversible hepatotoxicity. These adverse events halted further dose escalation. A total of 46 participants were enrolled in phase II; results are on the 51 participants who received therapy at dose level 1, the maximum tolerated dose. Diagnoses included neuroblastoma (26), sarcoma (9), lymphoma (8), brain tumors (5), Wilms (2) and retinoblastoma (1). Twenty participants (39.3%) were in CR1 at enrollment; median age was 5.1 years. Most common non-hematological grade IIIIV toxicity was gastrointestinal (n37). Neutrophil and platelet engraftment occurred at a median of 15 and 24 days, respectively. Twenty-six (51%) participants remain alive at a median of 6.4 years after AHCT. CY 3.75 g/m 2, and targeted topotecan followed by AHCT are feasible and produce acceptable toxicity in children with high-risk malignancies.

AB - Fifty-eight consecutive children with high-risk malignancies were treated with CY, and targeted topotecan followed by autologous hematopoietic cell transplantation (AHCT) in a phase I/II Institutional Review Board-approved study. Twelve participants enrolled in phase I; 5 received dose level 1 of topotecan 3 mg/m2 per day, with subsequent doses targeted to total systemic exposure of 100±20 ng h/mL and CY 750 mg/m2 per day. Seven participants received dose level 2. CY dose escalation to 1 g/m 2 per day was considered excessively toxic; one died from irreversible veno-occlusive disease and two experienced reversible hepatotoxicity. These adverse events halted further dose escalation. A total of 46 participants were enrolled in phase II; results are on the 51 participants who received therapy at dose level 1, the maximum tolerated dose. Diagnoses included neuroblastoma (26), sarcoma (9), lymphoma (8), brain tumors (5), Wilms (2) and retinoblastoma (1). Twenty participants (39.3%) were in CR1 at enrollment; median age was 5.1 years. Most common non-hematological grade IIIIV toxicity was gastrointestinal (n37). Neutrophil and platelet engraftment occurred at a median of 15 and 24 days, respectively. Twenty-six (51%) participants remain alive at a median of 6.4 years after AHCT. CY 3.75 g/m 2, and targeted topotecan followed by AHCT are feasible and produce acceptable toxicity in children with high-risk malignancies.

KW - autologous BMT

KW - CY

KW - lymphoma

KW - neuroblastoma

KW - sarcoma

KW - topotecan

UR - http://www.scopus.com/inward/record.url?scp=84869089853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869089853&partnerID=8YFLogxK

U2 - 10.1038/bmt.2012.51

DO - 10.1038/bmt.2012.51

M3 - Article

C2 - 22426752

AN - SCOPUS:84869089853

VL - 47

SP - 1448

EP - 1454

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -